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Chronic lymphocytic leukemia is a malignancy of mature B cellsthat strongly depend on microenvironmental factors, and theirdeprivation has been identified as a promising treatment
approach for this incurable disease. Cytokine array screening of 247
chronic lymphocytic leukemia serum samples revealed elevated levels of
tumor necrosis factor (TNF) receptor-1 which were associated with poor
clinical outcome. We detected a microenvironment-induced expression
of TNF receptor-1 in chronic lymphocytic leukemia cells in vitro, and an
aberrantly high expression of this receptor in the proliferation centers of
patients’ lymph nodes. Stimulation of TNF receptor-1 with TNF-α
enhanced nuclear factor κ-light-chain-enhancer of activated B cells 
(NFκB) activity and viability of chronic lymphocytic leukemia cells,
which was inhibited by wogonin. The therapeutic effects of wogonin
were analyzed in mice after adoptive transfer of Em-T-cell leukemia 1
(TCL1) leukemic cells. Wogonin treatment prevented leukemia develop-
ment when given early after transplantation. The treatment of full-
blown leukemia resulted in the loss of the TNF receptor-1 on chronic
lymphocytic leukemia cells and their mobilization to blood. Targeting
TNF receptor-1 signaling is therefore proposed for the treatment of
chronic lymphocytic leukemia. 
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy that is tightly regu-
lated by and dependent on microenvironmental stimuli provided in lymphoid tis-
sues.1  CLL cells in this protective niche show increased resistance to spontaneous
and drug-induced apoptosis which is causative for CLL progression and relapse. 
In vitro studies using co-cultures of CLL and non-malignant accessory cells mirrored
this dependency, and identified several CLL-relevant factors and pathways.2-4
Comparative gene expression profiling of CLL cells isolated from peripheral blood
(PB), bone marrow (BM) and lymph nodes (LN) further identified enhanced B-cell
receptor (BCR)-mediated signaling and nuclear factor κ-light-chain-enhancer of
activated B cells (NFκB) activity in the lymphoid microenvironment compared to
blood.5 In accordance with this, CLL cell migratory capability and tissue homing
were shown to influence disease pathogenesis and progression.6 Data from clinical
trials revealed that treatment with kinase inhibitors targeting BTK, SYK or PI3K-d
leads to transient lymphocytosis accompanied by LN shrinkage due to CLL cell
mobilization to PB.7-9 This impairment of CLL cell homing to lymphoid tissues sub-
stantially contributes to the observed high efficacy of
these inhibitors.10-11 Albeit, despite their clinical success,
CLL remains an incurable disease due to clonal evolution
of malignant cells under treatment, followed by drug
resistance and relapse.12 The current challenge is to devel-
op new strategies by targeting not only CLL cells, but also
the microenvironment, with the goal being that of eradi-
cating the malignant cells.
Tumor necrosis factor (TNF)-α and its receptors (TNFR)
have been identified in the sera of CLL patients in
increased concentrations, and high TNF-α levels are
indicative for an aggressive disease, thus suggesting a role
in CLL progression.13-16 TNF-α was shown to act as an
autocrine growth factor in CLL.17,18 The inhibition of TNFR
signaling by etanercept, a recombinant TNFR-2 derivative,
in combination with the anti-CD20 antibody rituximab,
caused durable remissions in refractory patients without
17p deletion.19 However, the detailed pathomechanism of
TNFR signaling in CLL development and progression
remains largely unknown. TNF-α is a pro-inflammatory
cytokine that exerts its pleiotropic effects via two recep-
tors, TNFR-1 (P55) and TNFR-2 (P75).20 Only TNFR-1 is
endowed with an intracellular death domain, and can
thereby induce either caspase-mediated apoptosis or pro-
survival signals via NFκB activation.21 TNF-α-induced
NFκB activation was shown to be blocked by wogonin, a
naturally occurring flavonoid, resulting in a shift of TNFR-
1 signaling towards apoptosis induction.22 In a multitude
of in vitro and in vivo studies, wogonin has been demon-
strated to exert anti-oxidant, anti-inflammatory and anti-
tumor activities.23
To elucidate the oncogenic role of TNFR-1 in CLL and
to test its potential as a therapeutic target, we analyzed
TNFR-1 expression and function in primary CLL cell co-
cultures and Em-T-cell leukemia 1 (TCL1) mice in the
presence and absence of wogonin, and used these plat-
forms for pre-clinical evaluation of TNFR-1 as a drug tar-
get in CLL. 
Methods
Samples
PB of CLL patients (Online Supplementary Table S1) and healthy
donors (HD) was obtained after informed consent and in accor-
dance with the Declaration of Helsinki. The study was approved
by the Institutional Review Board. 
Quantification of Soluble TNFR-1
Sera from 247 CLL patients from the German CLL8 study
(Online Supplementary Table S2) and from 50 age- and sex-matched
healthy controls were used to quantify soluble TNFR-1 by cyto-
metric bead arrays (BD Biosciences, Heidelberg, Germany),
according to the manufacturer's protocol. Capture beads were
synthesized by coupling anti-TNFR-1 antibody (Duoset, R&D
Systems, Minneapolis, MN, USA) to functionalized beads. A
biotinylated detection antibody (Duoset, R&D Systems) and a
streptavidin conjugate were used for visualization. Data was
acquired on a FACSCanto II flow cytometer and analyzed with
FCAP software (BD Biosciences). 
Sera from final stage leukemic Em-TCL1 mice24 presenting with
splenomegaly and more than 90% leukemic cells in the blood, and
matched wild-type (WT) controls were screened for 144 inflam-
matory factors using Mouse Cytokine Array G2000 (RayBiotech,
Norcross, GA, USA), according to the manufacturer’s protocol.
Glass slides were scanned on an Agilent microarray scanner
(Agilent Technologies, Santa Clara, CA, USA) and data was ana-
lyzed using GenePix Pro software (Molecular Devices, San José,
CA, USA).
Serum soluble (s)TNFR-1 was quantified in mice after adoptive
transfer (AT) of CLL using mouse sTNFR-1 enzyme-linked
immunosorbent assay (ELISA)  kit (R&D Systems).
Statistical analysis 
Details of statistical analysis are provided in the Online
Supplementary Methods.
Gene expression analysis
CLL cells and CD19-sorted B cells of HD were cultured for one
day in high cell density (1x107 cells in 4 mL per well in 6-well
plates) and total ribonucleic acid (RNA) was isolated before (day 0
[d0]) and after culture (d1). Microarray-based transcriptome analy-
sis and quantitative reverse transcription- polymerase chain reac-
tion (RT-PCR) was performed as previously described.3
Tissue microarrays and immunohistochemistry
Tissue microarrays (TMAs) including BM trephines (n=20 CLL
patients; n=16 HD), LN sections (n=58 CLL patients; n=14 coinci-
dental LN taken for non-malignant pathologies with no evidence
of germinal center formation), and reactive LNs (n=28) were
stained with hematoxylin and eosin (H&E) and antibodies against
CD20 (Dako, clone L26, Agilent), TNFR-1 (polyclonal, Abcam,
Cambridge, UK), CD3 (Labvision, clone SP7, ThermoFisher), and
CD68 (Dako, clone KP1, Agilent), as detailed in Online
Supplementary Methods. 
Animal models and treatments 
AT of TCL1 splenocytes was performed as previously
described.25 Briefly, 6-8-week-old C57BL/6 WT females (Charles
River Laboratories, UK) were transplanted with 4x107 splenocytes
pooled from leukemic TCL1 mice24 (>95% CD19+CD5+ cells) via
tail vein injection. In early treatment studies, animals were ran-
domized to daily treatment with 40 mg/kg wogonin in H2O con-
taining arginine as an adjuvant to improve the solubility of wogo-
nin, administered by intraperitoneal (i.p.) injection from 48 hours
after AT for three weeks. For late treatment studies, PB tumor load
was determined 21 days post-AT and animals were randomized to
treatment with phosphate buffered saline (PBS) or 40 mg/kg
wogonin (BIOTREND Chemicals AG, Wangen, Switzerland)
solved in dimethyl sulfoxide (DMSO) for 21 days using daily oral
gavage. At the endpoints, serum, peritoneal exudate, PB and sin-
gle-cell suspensions of lymphoid organs were prepared as
described previously.26 
Results
sTNFR-1 serum level predicts overall survival and
tumor-associated deaths in CLL
sTNFR-1 was quantified in serum from 247 CLL
patients (Online Supplementary Table S2) and 50 age- and
sex-matched controls by cytometric bead arrays. The
analysis revealed a significantly higher median serum con-
centration of sTNFR-1 in CLL patients (2.30 ng/mL, range:
0.50-7.31) compared to controls (1.35 ng/mL, range: 0.76-
1.74; P<0.0001; Figure 1A). Further, sTNFR-1 serum con-
centrations moderately but significantly correlated with
β2-microglobulin (R=0.582; P<0.001; Figure 1B) and
thymidine kinase (R=0.263; P<0.001; Figure 1C) serum
levels, suggesting the malignant cells as the source of
TNF receptor signaling as therapeutic target in CLL
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sTNFR-1. Of interest, high sTNFR-1 concentrations signif-
icantly correlated with shorter overall survival (OS) (Figure
1D) and a higher incidence of tumor-associated deaths
(TAD) (Figure 1E) when evaluated in a univariable Cox
hazard model. Moreover, multivariate analysis revealed
that sTNFR-1 represents a prognostic marker for OS and
TAD irrespective of age, IGHV mutational status, 11q
deletion, 17p deletion, and rituximab treatment (Online
Supplementary Table S3).
Microenvironment-induced expression of TNFR-1 in CLL
but not in healthy donor B cells
Culturing CLL cells in high cell density provides survival
supportive stimuli to the leukemic cells that would other-
wise die by spontaneous apoptosis. To identify survival-
stimulating pathways in CLL, we performed microarray-
based gene expression profiling of CLL cells or HD B cells
before and after one day of cultivation in high cell densi-
ties. Comparative analyses of the data obtained resulted in
a list of 236 genes that were significantly different in their
regulation between CLL and normal B cells (Online
Supplementary Table S4 lists genes with the highest differ-
ence between CLL and HD). Among them, TNFR-1
(TNFRSF1A) appeared as one of the top upregulated tran-
scripts in CLL (mean log2 fold change (FC) d1 vs. d0 =2.06),
but not in HD (FC=-0.18). This finding was validated by
quantitative RT-PCR using CD19-sorted CLL or normal B
cells, confirming the induced expression of TNFR-1 in
three out of four CLL samples (mean FC=10.13; SEM ±
3.27) but not in HD B cells (Figure 2A). We further detect-
ed significantly enhanced levels of membrane-bound
TNFR-1 (mTNFR-1) in CLL cells by flow cytometry, with
a mean relative median fluorescence intensity (MFI) of
1.37 (SEM ± 0.06) on freshly isolated CLL cells, and 7.35
(SEM ± 1.36) after one day of cultivation in high cell den-
sity (P<0.001; Figure 2B). 
To further investigate a microenvironment-dependent
regulation of TNFR-1 expression, we cocultured CD19-
sorted CLL or healthy B cells for one day with CD14-sort-
ed monocytes that have previously been shown to sup-
port CLL cell survival,4 and observed upregulated mTNFR-
1 expression in CLL cells by 4.08-fold (SEM ± 0.70), while
healthy B cells remained negative (P=0.001; Figure 2C).
TNFR-1 expression in CLL cells further increased in co-
cultures over seven days with a mean relative MFI of 7.85
(SEM ± 2.62) compared to 1.37 (SEM ± 0.01) in healthy 
B cells (Figure 2D). Similar results were obtained by cultur-
ing CLL cells in medium containing at least 20% human
serum. 
Previous work has suggested that CLL cells that have
recently divided in lymphoid tissues, emigrate to PB as
CXCR4dimCD5bright cells.27 Over time, they begin to re-
express CXCR4 and lose CD5 expression, before entering
the lymphoid system again. To test whether TNFR-1
expression is higher in CLL cells that have just left the
lymphoid microenvironment, we compared TNFR-1 lev-
els on  CXCR4dimCD5bright and CXCR4brightCD5dim CLL cells
from fresh blood samples of four patients, but did not
observe any significant differences between the two cell
subsets (data not shown).
These data suggest that TNFR-1 expression is induced in
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Figure 1. Elevated sTNFR-1 serum levels have prognostic relevance in CLL. (A) Serum levels of sTNFR-1 in 247 CLL patients and 50 age and sex-matched healthy
donors were assessed by flow cytometry using bead arrays. The lines indicate mean concentrations. Significance analysis was performed via unpaired t-test with
Welch's correction (***P<0.0001). (B) Correlations of sTNFR-1 and β2-microglobulin, (C) as well as thymidine kinase concentrations in serum samples of 247 CLL
cases are depicted. (D) Associations of log2 sTNFR-1 serum concentration and overall survival, (E) along with tumor-associated deaths of CLL patients were assessed
by Cox hazard model with log2 sTNFR-1 concentration as a continuous variable. Results are depicted in a Stone-Beran estimator, with the Stone-Beran estimate at
the highest concentration shown as a blue line, the Stone-Beran estimate at the median concentration shown as a green line, and the Stone-Beran estimate at the
lowest concentration shown as a black line. sTNFR-1: soluble tumor necrosis factor receptor-1.
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CLL cells by microenvironmental stimuli, and the receptor
is quickly shed from the cell surface when cells enter PB,
which presumably leads to abnormally high TNFR-1
serum levels.
mTNFR-1 expression is restricted to B cells within 
proliferation centers
To verify microenvironment-regulated expression of
TNFR-1 in vivo, we performed immunohistochemical
(IHC) analysis of LN and BM sections of CLL patients and
HD using antibodies specific for TNFR-1, CD20, Ki-67,
CD3, and CD68. In so doing, we observed co-localization
of TNFR-1 with CD20 (B-cell marker) and Ki-67 (prolifer-
ation marker; Figure 3A), but not with CD3 (T-cell marker)
or CD68 (marker for myeloid cells), suggesting B cell-spe-
cific expression of TNFR-1. In LNs, TNFR-1 positive cells
were mainly located within proliferation centers consist-
ing of Ki-67 positive, large, round paraimmunoblasts in
nodular areas (Figure 3A). The percentage of TNFR-1 pos-
itive cells significantly correlated with that of Ki-67 posi-
tive cells (R=0.39; P<0.0001; Figure 3B), and was slightly
higher in CLL-derived LN sections (n=58) with 10.68%
(SEM ± 1.93) compared to non-CLL samples (n=14) with
7.76% (SEM ± 3.42) TNFR-1 positive B cells (Figure 3C).
In both groups, the results were very heterogeneous, rang-
ing from 0.1-51.33% in CLL and from 0-38.34% in non-
CLL samples. Analysis of reactive LN sections (n=30)
revealed a clear accumulation of TNFR-1 in germinal cen-
ters with 17.48% (SEM ± 0.135) positive B cells compared
to 1.74% (SEM ± 0.26) in the mantle zone (MZ; P<0.0001;
Figure 3D). In BM biopsies of CLL patients (n=20), 4.12%
(SEM ± 0.65) of the CD20 positive cells co-expressed
TNFR-1, whereas significantly fewer co-expressing cells
were detected in BM biopsies of HD (n=16; 2.38% SEM ±
0.46; P=0.04; Figure 3E). Altogether, these data show that
mTNFR-1 is expressed by proliferating CLL cells that are
localized in the LN and BM as well as by proliferating non-
malignant B cells in germinal centers of reactive LN.
TNF-α induced NFκB activation and survival of CLL
cells in vitro is reduced by wogonin
To study the downstream effects of TNFR-1 signaling in
CLL, we cultured peripheral blood mononuclear cells
(PBMC) from CLL patients (n=3) in 50% human serum for
TNF receptor signaling as therapeutic target in CLL
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Figure 2. TNFR-1 expression in CLL cells is regulated by the microenvironment. (A) TNFR-1 transcript levels were analyzed by quantitative RT-PCR using CD19-sorted
CLL cells (n=4) or healthy donor (HD) B cells (n=3) before (day [d]0) and after 1 day (d1) of cultivation in high cell density (2.5 x 106 cells/mL). Results were normalized
to the mean expression levels of HPRT, DCTN2, and PGK. (B) A total of 4 x 105 CLL peripheral blood mononuclear cells (PBMC) were cultured for 1 day in 200 mL
complete medium in 96-well plates. Cell surface expression of TNFR-1 (mTNFR-1) was quantified by flow cytometry in freshly isolated cells (d0) and after 1 day of
cultivation (d1; n=14). Relative median fluorescence intensity (MFI) of TNFR-1 normalized to isotype control staining was assessed by gating on CD20+ lymphocytes.
Lines indicate means and SEM. Significance was calculated by paired Student's t-test (***P=0.0005). (C+D) A total of 5 x 105 CD19-sorted CLL cells or healthy B
cells were cocultured with 1 x 105 CD14-sorted monocytes for 1 or 7 days in 400 mL complete medium in 48-well plates. mTNFR-1 was quantified on CD20+ lympho-
cytes by flow cytometry in freshly isolated cells (d0) and after cultivation (d1 and d7). Results are depicted as ratios of relative MFI on d1 or d7 versus d0. Lines show
mean and SEM. Unpaired t-test with Welch's correction was applied for significance analysis (**P=0.001). CLL: chronic lymphocytic leukemia; PB: peripheral blood;
mTNFR-1: membrane-bound TNFR-1.
one day, which induced TNFR-1 expression. Stimulation
of these cells with TNF-α significantly enhanced NFκB
activity, as quantified by p65 binding to immobilized
NFκB consensus sequence oligonucleotides (relative mean
chemiluminescence intensity (MLI): 19.25; SEM ± 1.72),
and could be blocked by neutralizing TNF-α-specific anti-
body (MLI: 3.45; SEM ± 1.14; P=0.001; Figure 4A).
Treatment of these cultures with the flavonoid wogonin,
known to impair TNF-α-induced NFκB signaling,22 result-
ed in a reduction of relative MLI from 2.78 (SEM ± 0.60)
to 0.98 (SEM ± 0.53; Figure 4B), indicating that wogonin
abolished TNF-α-induced NFκB activity. Next, the effect
of TNF-α in combination with wogonin on cell survival
was examined. After the induction of TNFR-1 expression
by 1 day of culture in high cell densities, CLL cells were
treated with increasing concentrations of wogonin, 30
minutes prior to the administration of TNF-α. Wogonin
treatment for 24 h resulted in a concentration-dependent
reduction in cell viability, that was significantly stronger in
the presence of TNF-α (Figure 4C). Treatment with 50 µM
wogonin reduced average cell survival from 64.15% (SEM
± 1.80) to 44.72% (SEM ± 4.16; P=0.0003), which was fur-
ther reduced to 37.92% (SEM ± 5.22; P=0.002) and
31.33% (SEM ± 2.99; P=0.004) in the presence of 10 and
50 ng/mL TNF-α, respectively. At 100 mM wogonin, sur-
vival was reduced to 27.39% (SEM ± 2.95) in the absence
of TNF-α, and furthermore, to 22.13% (SEM ± 2.67;
P=0.01) and 21.63% (SEM ± 3.31; P=0.009) in the presence
of 10 and 50 ng/mL TNF-α, respectively. These results
suggest that wogonin impacts on CLL cell viability in vitro
by inhibiting TNF-α-mediated survival signals.
TNFR-1 expression and serum levels are mirrored in
the Eµ-TCL1 mouse model of CLL
To investigate whether the Em-TCL1 mouse line, a well-
established animal model of CLL,24 mirrors our findings of
TNFR-1 in human CLL, we first analyzed the serum of
mice with end-stage leukemia (n=5), and confirmed an
average of 3.2-fold higher levels of sTNFR-1 as compared
to control animals (n=3; data not shown). A significant
C. Dürr et al.
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Figure 3. TNFR-1 is expressed by proliferating B cells in bone marrow and lymph nodes. Immunohistochemical staining of tissue microarrays containing lymph node
(LN) sections and bone marrow (BM) trephine biopsies of CLL patients and healthy donors (HD) as well as sections of reactive LN were performed using CD20, Ki-
67 and TNFR-1 specific antibodies. (A) Representative micrographs of Ki-67 and TNFR-1 staining of a CLL LN section. (B) Correlation of percentages of Ki-67 positive
cells and TNFR-1 positive cells in 58 CLL samples (38 LN and 20 BM). (C) CD20 positive B cells that co-expressed TNFR-1 were quantified in LN sections of CLL
patients (n=38) and HD (n=14); (D) in germinal centers (GC) and marginal zones (MZ) of reactive LN sections (n=30); (E) and BM trephine biopsies isolated from
CLL patients (n=20) and HD (n=16). Lines indicate mean percentage of TNFR-1 positive cells and SEM. Unpaired t-test with Welch's correction was applied for sig-
nificance analysis (***P<0.0001; *P=0.04). ). CLL: chronic lymphocytic leukemia; TNFR-1: tumor necrosis factor receptor-1.
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increase of sTNFR-1 serum levels was further induced in
young syngeneic WT animals after AT of splenocytes
from leukemic Em-TCL1 mice, which resulted in reliable
and homogeneous development of CLL as formerly
described.25,28 Mean concentrations of sTNFR-1 42 days
after transplantation were 2.79 ng/mL (SEM ± 0.23) in
TCL1 AT mice (n=7) and 2.04 ng/mL (SEM ± 0.23) in WT
mice (n=6; P=0.04; Figure 5A). In addition, analysis of
mTNFR-1 by flow cytometry in murine CD19+CD5+ CLL
cells isolated from different tissue sites revealed signifi-
cantly higher mTNFR-1 expression in the spleen, with a
mean MFI of 3.53 (SEM ± 0.28) compared to 1.84 (SEM
0.28) in PB (P<0.001; Figure 5B), suggesting that microen-
vironmental regulation of TNFR-1 expression in malignant
cells is mirrored in the Em-TCL1 model.
Wogonin reduces CLL development in the TCL1 
adoptive transfer model
As wogonin impaired NFκB activation and survival of
CLL cells in vitro, we investigated its impact on leukemia
development in the TCL1 AT model. Two days after
transplantation of malignant cells, mice were randomized
to daily treatment with 40 mg/kg wogonin or PBS by i.p.
injection for three weeks (n=10; Figure 6A). Eight out of
ten mice analyzed in this study responded to wogonin
treatment with significantly lower spleen weights of an
average of 0.25g (SEM ± 0.06) in treated mice as compared
to 0.36g (SEM ± 0.04) in the control cohort (P=0.03; Figure
6B). To assess tumor load in all affected tissues, percent-
ages of CD19+CD5+ cells of viable CD45+ cells were ana-
lyzed in the spleen, PB and peritoneal cavity (PC) by flow
cytometry. As depicted in Figure 6C, control mice exhibit-
ed a median splenic tumor load of 23.78% (SEM ± 5.37),
whereas CLL cells were almost completely absent in the
eight mice responding to wogonin; the mean percentage
of CLL cells in all treated animals, including the two non-
responders, was 13.42% (SEM ± 7.32). Further, the CLL
cell content was reduced by wogonin treatment from
31.14% (SEM ± 5.63) to 18.79% (SEM ± 5.99) in PB (Figure
6D), and from 56.31% (SEM ± 6.78) to 32.55% (SEM ±
10.67) in PC (Figure 6E). The proliferation rate of CLL cells
in vivo was assessed by i.p. injection of 200 mg EdU 20 h
prior to euthanization of mice, which confirmed the
reduced proliferative activity of CLL cells in mice respond-
ing to wogonin treatment (Figure 6F). The data was too
heterogeneous to reach significance, due to two animals
that did not respond to treatment. But in the majority of
mice, wogonin was able to control CLL development.
Wogonin impacts on TNFR-1 expression in vivo
The effect of wogonin was further investigated in mice
with advanced disease where treatment was started 21
days after AT of CLL (Figure 7A). Mice were gavaged daily
with either 40 mg/kg/d wogonin (n=5) or PBS (n=9) for
three weeks. No significant difference in spleen weight was
observed upon wogonin treatment (0.92g, SEM ± 0.13 in
treated versus 1.08g, SEM ± 0.08 in control mice; Figure 7B),
although there was a tendency, in the treated group, of
slightly smaller spleens. Similar results were obtained for
tumor load in the spleen, which was 61.10% (SEM ± 4.48)
in wogonin-treated versus 68.28% (SEM ± 3.18) in control
mice (Figure 7C). By contrast, the percentage of
CD19+CD5+ cells in PB was significantly increased in treat-
ed mice (74.67%, SEM ± 3.82) compared to controls
(58.84%, SEM ± 3.39; P=0.01; Figure 7D). This significant
increase persisted when CLL cell percentages after treat-
ment were normalized to CD19+CD5+ percentages at the
start of treatment, which was three weeks after AT of CLL
(P=0.04; Figure 7E). To analyze whether this effect might be
linked to the interference of wogonin with TNFR-1 signal-
ing, we analyzed mTNFR-1 expression on splenic CLL cells
after treatment. Interestingly, wogonin induced an almost
complete loss of mTNFR-1 expression in CLL cells (MFI
1.50 in treated versus 3.53 in control mice; P=0.02; Figure
7F). This is most likely due to receptor shedding, since
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Figure 4. TNF-α-induced NFκB activity in CLL cells is inhibited by wogonin. (A) 2 x 107 CLL PBMC (n=3) were treated with 100 ng/mL TNF-α or PBS as control in 400
mL complete medium with or without TNF-α-blocking antibody (15 mg/mL). After 30 min, NFκB activity was assessed via an oligo-based chemiluminescence ELISA
that detects binding of p65 to NFκB consensus binding sequence (wt), and was normalized to p65 background binding to a mutated oligo (wt – mut). Mean values
and respective SEMs are depicted relative to PBS control. Paired Student's t-test was applied for significance analysis (**P=0.001). (B) NFκB activity in 1 x 107 CLL-
derived PBMC (n=2) upon addition of 100 ng/mL TNF-α for 30 minutes in the presence or absence of 50 mM wogonin was assessed as described in (A). Results
are depicted as mean values and SEMs relative to DMSO control (1%). (C) A total of 4 x 105 CLL PBMC were cultured for 1 day in 200 mL complete medium in 96-
well plates. On day 2, wogonin and TNF-α were added either alone, or in combination, at the concentrations indicated. 1% DMSO was used as untreated control.
Cell survival was assessed after a further 24 h via flow cytometry by gating on annexin V-PE/7-AAD-negative cells. Results are depicted as mean survival rates and
SEM of 5-8 samples. Paired Student's t-test was applied for significance analysis (*P<0.05; **P<0.01). PBS: phosphate buffered saline; wt: wild-type; mut: mutated;
DMSO: dimethyl sulfoxide; NFκB: nuclear factor κ-light-chain-enhancer of activated B cells; TNF-α: tumor necrosis factor-α. 
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quantification of sTNFR-1 in the serum of these mice by
ELISA revealed significantly higher levels of 4.22 ng/mL
(SEM 0.34 ng/mL) in wogonin-treated mice compared to
2.79 ng/mL (SEM 0.23 ng/mL) in control mice (P=0.005;
Figure 7G). This increase in sTNFR-1 levels in wogonin-
treated mice is not a sign of disease progression, but rather
a treatment effect, including enhanced TNFR-1 shedding
and mobilization of leukemic cells from the spleen to PB.
Despite the fact that wogonin failed to effectively control
advanced disease in mice, it had an impact on TNFR-1
expression, and was associated with an increased accumu-
lation of malignant cells in PB, suggesting that prolonged
treatment with wogonin, or combinations with other
drugs, might lead to CLL-effective responses.  
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Figure 5. CLL-associated TNFR-1 expression in Eµ-TCL1 mice. (A) Syngeneic, immunocompetent C57BL/6 mice were injected (i.v.) with 4 x 107 splenocytes from fully
leukemic Em-TCL1 mice (TCL1 AT; n=7). Non-transplanted C57BL/6 mice (WT; n=6) were used as controls. Serum concentrations of sTNFR-1 were quantified 42 days
after CLL cell engraftment via ELISA. Lines indicate mean concentrations and SEM. Unpaired Student's t-test was applied for significance analysis (*P=0.04). (B)
Single cell suspensions of peripheral blood (PB) and spleen (SP) of TCL1 AT mice (n=9) 42 days after transplantation were analyzed for mTNFR-1 expression by flow
cytometry by gating on CD45+CD5+CD19+ CLL cells. Staining of relative MFI values normalized to isotype control are depicted. Values for PB (dots) and spleen
(squares) samples of each mouse (1-9) are connected by dotted lines. Paired Student's t-test was applied for significance analysis (P<0.0001). MFI: median fluo-
rescence intensity; IgG: immunoglobulin G; sTNFR-1: soluble tumor necrosis factor receptor-1: mTNFR-1: membrane-bound TNFR-1.
Figure 6. Wogonin reduces leukemia development in the TCL1 adoptive transfer model. (A) Syngeneic, immunocompenent C57BL/6 mice were injected (i.v.) with 4
x 107 splenocytes from fully leukemic Em-TCL1 mice. Two days after transplantation, mice were either treated with 40 mg/kg/d wogonin (n=10) or PBS (ctl; n=10) by
i.p. injections. Mice were sacrificed after 21 days of treatment. Serum and organs were collected. (B) Spleen weight of wogonin-treated and control mice was assessed
after 21 days of treatment. (C-E) Single cell suspensions were collected from the spleen (SPL), blood (PB) and peritoneal cavity (PC). Tumor load was assessed by
flow cytometry staining and is indicated as CD5+ CD19+ cells out of CD45+ cells in (C) SPL, (D) PB, (E) and PC. (F) Mice were injected i.p. with 0.1 mg/g EdU 20 h
before sacrificing, and EdU incorporation in spleen CD5+ CD19+ malignant cells was analyzed after Click-iT reaction by flow cytometry. Lines in all graphs indicate
mean values and SEM. Paired Student's t-test was applied for significance analysis (*P=0.03). d: day; g: gram; ctl: control.
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Discussion
The relevance of microenvironmental interactions that
mediate pro-survival signaling in CLL is now generally
accepted. This is, however, thus far mainly based on in
vitro studies, and their role in vivo still remains ill-defined.
Interfering with the crosstalk of CLL cells and their
microenvironment and thereby depriving malignant cells
from supportive factors has become an attractive novel
approach for treatment. 
In the study herein, we identified TNFR-1 as a pivotal
player in CLL pathology. We observed significantly elevat-
ed sTNFR-1 serum levels in CLL patients, in line with
results from Digel et al.16 We further showed that sTNFR-
1 levels correlate with β2-microglobulin and thymidine
kinase serum levels, which are indicative for tumor load as
well as with OS and TAD of CLL patients. Thereby, the
prognostic power of sTNFR-1 was independent of estab-
lished prognostic markers. These findings are in line with
observed correlations of serum sTNFR-1 and disease
aggressiveness in CLL, breast, colon, and pancreatic can-
cer.15,16,29 We further showed that CLL development in Em-
TCL1 mice is associated with elevated TNFR-1 serum lev-
els. Taken together, our findings determine sTNFR-1 as a
predictor for disease progression in CLL. 
Albeit conflicting data has been presented concerning
the expression of mTNFR-1 on freshly isolated PB-derived
CLL cells,15,30,31 our results clearly demonstrate that these
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Figure 7. Wogonin impacts on TNFR-1 expression in vivo. (A) Adoptive
transfer of TCL1 splenocytes was performed as described in Figure 6.
At d21 after transplantation, mice were treated either with 40
mg/kg/d wogonin (n=5) or PBS (ctr; n = 9) by daily oral gavage. Mice
were sacrificed after 21 days of treatment. Serum and organs were
collected. (B) Spleen weight of wogonin-treated and control mice was
assessed after 21 days of treatment (d42). (C-E) Single cell suspen-
sions were collected from spleen (SPL) and blood (PB; d42). Tumor
load was assessed by flow cytometry staining and is indicated as
CD5+CD19+ cells out of CD45+ cells in (C) SPL and (D) PB (*P=0.01).
(E) Percentage tumor load in blood was further normalized to percent-
age at start of treatment in each mouse and is presented as ratio of
d42 over d21 (*P=0.04). (F) TNFR-1 expression was quantified on
CD5+CD19+ cells via flow cytometry relative to isotype control antibody
(mTNFR-1; *P=0.02). (G) Serum sTNFR-1 concentration was assessed
by ELISA (**P=0.005). Lines in all graphs indicate mean values and
SEM. Paired Student's t-test was applied for significance analysis. d:
day; g: gram; ctl: control; MFI: median fluorescence intensity; IgG:
immunoglobulin G; sTNFR-1: soluble tumor necrosis factor receptor-1:
mTNFR-1: membrane-bound TNFR-1.
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are negative for mTNFR-1, but upregulate their expression
upon in vitro cultivation. Consistent with our data, TNFR-
1 expression was reported on malignant cells in diffuse
large B-cell lymphoma (DLBCL), which correlated with
significantly shorter OS and progression-free survival rates
compared to patients with TNFR-1 negative lymphoma
cells.32 TNFR-1 induction upon malignant transformation
has also been described in colorectal adenoma and
prostate cancer, underlining its role in carcinogenesis.33,34
BCR and TNFR signaling as well as canonical NFκB
activity characterize the LN microenvironment in CLL.5,35
TNFR-1 is a pleiotropic receptor which induces either cel-
lular activation via NFκB or apoptosis via activation of cas-
pases. NFκB activation appears to be the default pathway
resulting in expression of anti-apoptotic proteins, whereas
specific inhibition of NFκB prior to TNF-α stimulation
triggers cell death.36 Our data, procured from tissue
microarray staining of human BM and LN sections, sug-
gests that TNFR-1 signaling contributes to NFκB activity
in CLL cells. Thereby TNFR-1 expression was enriched
within B-cell rich proliferation centers in CLL samples and
germinal centers in reactive LN, the sites of NFκB activi-
ty.37 Along the same line, malignant B cells in the blood of
Em-TCL1 mice were negative for TNFR-1, but upregulated
the receptor upon recirculation to the spleen, stressing the
hypothesis that TNFR-1 might be involved in CLL cell
activation and survival maintenance.
Inflammatory pathways are central for CLL cell
survival.3 In agreement with this fact, elevated TNF-α lev-
els were identified in CLL patients and correlated with
poor prognosis.13-15 Nonetheless, data on the role of TNF-
α in CLL pathogenesis are controversial. It has been sug-
gested that it acts as an autocrine and paracrine growth
factor which induces CLL cell proliferation in vitro.17,18,38
However, Foa et al. showed that in the majority of CLL
cases, proliferation was reduced upon TNF-α treatment.39
In our study, TNF-α had no effect on CLL cell proliferation
(data not shown), but rather induced canonical NFκB activi-
ty in CLL cells in vitro. Similar results were reported by
Coscia et al., who demonstrated that NFκB is activated in
CLL cells with unmutated IGHV genes upon TNF-α expo-
sure.40 
Clinical intervention with TNF/TNFR signaling in CLL
is currently restricted to global TNF-α neutralization,
using etanercept in combination with rituximab.19
However, less attention has been paid to the receptors
that mediate the pathogenic effect of TNF-α. In particular,
selective TNFR-1 inhibition showed promising results in
the treatment of inflammatory diseases in mice.41-43
Wogonin, a naturally occurring monoflavonoid, was
shown to attenuate TNF-α-conferred NFκB activity and
thereby sensitize malignant T cells to apoptosis.
Moreover, wogonin was reported to exert cytostatic and
cytotoxic activities against several cancer cell lines in vitro
and in vivo, accompanied by no or only mild side effects
and low toxicity for non-malignant cells.44-46 The mecha-
nism of action of wogonin is based on CDK9 inhibition
and interference with reactive oxygen species (ROS)
homeostasis.22,45 Wogonin was shown to shift the redox
status of malignant T cells to a more reduced state by
increasing H2O2 levels and decreasing ·O2 levels.22 This
resulted in an inhibition of the redox-sensitive protein
NFκB.47,48 In the study herein, wogonin reduced TNF-α-
mediated NFκB activity and induced apoptosis in CLL
cells. Future studies need to investigate whether this effect
is based on interference with ROS levels.
Pre-clinical testing of wogonin after adoptive transfer of
CLL in mice revealed that early treatment start resulted in
a reduced tumor load in all tissues affected by disease,
which might be due to the inhibition of tumor cell survival
or proliferation. Accordingly, studies with several cancer
cell lines showed that wogonin attenuates cyclin expres-
sion.44,49,50 When we treated animals with full-blown
leukemia, starting 21 days after tumor engraftment, wogo-
nin reduced the CLL cell content in the spleen and signifi-
cantly increased tumor load in PB. This effect was accom-
panied by the loss of mTNFR-1 expression in CLL cells
and elevated sTNFR-1 serum levels, suggesting that the
shedding of mTNFR-1 from the surface of CLL cells might
be causally involved in the observed accumulation of cells
in the blood. Targeting CLL cells with drugs that are cur-
rently used in clinical treatment for CLL is much more
effective in the blood. Therefore, combination therapy
approaches with wogonin and,  for example, therapeutic
antibodies like rituximab might result in improved treat-
ment responses.
C. Dürr et al.
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